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Abstract 
Sickle cell anaemia is one of the commonest chronic 
hemolytic anaemia in the Sudan; it is a disease with high 
mortality and morbidity. 
Six month descriptive, cross-sectional, hospital based 
study was conducted aiming to study the lung function in 
children with sickle cell anaemia, and to assess the relationship 
between the lung function abnormalities and the severity of the 
disease. 
The study was conducted in the referral clinics in 
Khartoum Children Emergency Hospital, Soba Teaching 
Hospital, Omdurman Teaching Hospital. 
The study group was 73 patients with sickle cell anaemia, 
ages range from 5 to 18 years. Data were collected in a designed 
questionnaire which include full history, examination, lung 
function study and hemoglobin concentration.  
Reduced peak expiration flow rate were detected in 31% of 
the patients. 
Obstructive lung disease was detected in 43% of the 
patients. 
 
 
 
Restrictive lung disease was detected in 46% of the 
patients. 
Both restrictive and obstructive lung disease was detected 
in 6% of the patients. 
Abnormal lung function correlated positively with severity 
index and previous attacks of acute chest syndrome. 
There is no correlation between abnormal lung function 
test and Hb concentration. 
  ﻣﻠﺨﺺ ﺍﻷﻃﺮﻭﺣﺔ
 ﻭﻫـﻮ –ﻳﻌﺘﺒﺮ ﻓﻘﺮ ﺍﻟﺪﻡ ﺍﻟﻤﻨﺠﻠﻲ ﻣﻦ ﺃﻛﺜﺮ ﺃﻧﻮﺍﻉ ﻓﻘﺮ ﺍﻟﺪﻡ ﺍﻷﻏﻼﻟﻲ ﺍﻟﻤﺰﻣﻦ ﺇﻧﺘﺸﺎﺭﺍﹰ ﻓﻲ ﺍﻟﺴﻮﺩﺍﻥ 
  .ﻣﺮﺽ ﺫﻭ ﻣﻌﺪﻝ ﻣﺮﺿﻲ ﻭﻣﻌﺪﻝ ﻭﻓﻴﺎﺕ ﻋﺎﻟﻲ 
ﺧﻼﻝ ﻓﺘﺮﺓ ﺯﻣﻨﻴﺔ ﺃﺳﺘﻤﺮﺕ ﺳﺘﺔ ﺃﺷﻬﺮ ﺃﺟﺮﻳﺖ ﺩﺭﺍﺳﺔ ﻋﻴﻨﺔ ﻧﻤﻮﺫﺟﻴﺔ ﻭﺿﻌﻴﺔ ﺃﻋﺘﻤﺪﺕ ﻋﻠﻰ ﺍﻟﻤﺮﺿﻰ 
  .ﺍﻟﺬﻳﻦ ﻳﺄﺗﻮﻥ ﺇﻟﻰ ﺍﻟﻤﺴﺘﺸﻔﻰ 
ﻣﻦ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﻫﻮ ﺩﺭﺍﺳﺔ ﻭﻇﺎﺋﻒ ﺍﻟﺮﺋﺔ ﻟﻸﻃﻔﺎﻝ ﺍﻟﻤﺼﺎﺑﻴﻦ ﺑﻔﻘـﺮ ﺍﻟـﺪﻡ ﻛﺎﻥ ﺍﻟﻬﺪﻑ  ♦
 .ﺍﻟﻤﻨﺠﻠﻲ ﻭﺗﺤﺪﻳﺪ ﻧﻮﻉ ﺍﻟﻌﻼﻗﺔ ﺑﻴﻦ ﻫﺬﻩ ﺍﻟﺤﺎﻻﺕ ﻭﺧﺎﺻﺔ ﺍﻟﻤﺮﺽ 
 –ﺣـﻮﺍﺩﺙ ﺍﻷﻃﻔـﺎﻝ }ﺃﺟﺮﻳﺖ ﻫﺬﻩ ﺍﻟﺪﺭﺍﺳﺔ ﻓﻲ ﺍﻟﻌﻴﺎﺩﺍﺕ ﺍﻟﻤﺤﻮﻟﺔ ﺑﻤﺴﺘﺸﻔﻰ ﺍﻟﺨﺮﻃﻮﻡ  ♦
 .{ ﻣﺴﺘﺸﻔﻰ ﺃﻣﺪﺭﻣﺎﻥ ﺍﻟﺘﻌﻠﻴﻤﻲ ﻭﻣﺴﺘﺸﻔﻰ ﺳﻮﺑﺎ ﺍﻟﺠﺎﻣﻌﻲ
 ﻃﻔﻞ ﻣﻦ ﻣﺮﺿﻰ ﻓﻘﺮ ﺍﻟﺪﻡ ﺍﻟﻤﻨﺠﻠﻲ ﺗﺘﺮﺍﻭﺡ ﺃﻋﻤﺎﺭﻫﻢ ﺑـﻴﻦ 37ﻜﻮﻥ ﻣﻦ ﺍﻟﻔﺌﺔ ﺍﻟﻤﺨﺘﺎﺭﺓ ﺗﺘ  ♦
 . ﻋﺎﻣﺎﹰ 81ﺧﻤﺲ ﺳﻨﻮﺍﺕ ﻭ 
ﺍﻟﻤﻌﻠﻮﻣﺎﺕ ﺗﻢ ﺟﻤﻌﻬﺎ ﻓﻲ ﺷﻜﻞ ﺇﺳﺘﺒﻴﺎﻥ ﻳﺘﻀﻤﻦ ﺃﺳﺌﻠﺔ ﻋﻦ ﺗﺎﺭﻳﺦ ﺍﻟﻤﺮﺽ ﺇﺿـﺎﻓﺔ ﻟﻠﻔﺤـﺺ  ♦
 .ﺍﻟﺴﺮﻳﺮﻱ ﻟﻠﻤﺮﺿﻰ ﻭﺍﻟﻤﻌﻤﻠﻲ ﻟﺨﻀﺎﺏ ﺍﻟﺪﻡ 
ﻣﻦ ﺍﻟﻤﺮﺿﻰ ﺍﻟﺬﻳﻦ ﻳﻌﺎﻧﻮﻥ ﻣﻦ ﺇﻧﺨﻔـﺎﺽ ﻣﻌـﺪﻝ ﺍﻟﺘـﻨﻔﺲ ﺍﻟﺰﻓﻴـﺮﻱ % 13ﻭﺟﺪﺕ ﻓﻲ  ♦
 .ﺍﻷﻋﻠﻰ 
 .ﻣﻦ ﺍﻟﻤﺮﺿﻰ ﺑﺪﺍﺀ ﺍﻟﺮﺋﺔ ﺍﻹﻧﺴﺪﺍﺩﻱ % 34ﻭﺟﺪﺕ ﻓﻲ  ♦
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Chapter One 
1- Introduction 
 
1. Sickle Cell Anaemia: 
1.1 Definition: 
 Sickle cell disease is a group of inherited disorders with 
abnormalities caused by a single base mutation of adenine to 
thymine which results in a substitution of saline aminoacid for 
glutamic acid at the sixth codon   of the B-globin(1).  
 Sickle cell anaemia, in which only hemoglobin S is 
produced (HbSS) is the severest and most common form(2).  
 
1.2 Historical background: 
 Herrick in 1910 was the first to describe sickle cell 
anaemia in 20 years-old black west Indian student.  The youth 
had features that would be recognized today as typical sickle 
cell anaemia (pallor, jaundice, leg ulcers, generalized 
lymphadopathy and dark urine). 
 2
 Examination of erythocytes under microscope revealed 
odd-shapped cells, but what specially attracted his attention 
were the many thin sickle-shaped for forms (2). 
 The pathologic basis of the disorder and its relation to 
hemoglobin molecule were define in 1927 by Hahn and 
Gillespie(3). 
 Application of moving boundary electropharesis to 
separation of sickle form and normal haemoglobin was done 
by Paul and co-workers(4). 
 Beet and Veel defined the genetics of the disorder and 
clearly distinguished sickle cell triat i.e. the heterozygours 
conditions (AS) from sickle cell anaemia, i.e. the homozygous 
state (S.S) (5,6). 
 Using chromatography or zone electrophoresis by which 
sickle hemoglobin could be isolated.  Ingram (1975) identified 
the nature of the defect as the amino acid substitution in 
sickle hemoglobin is a valine  amino acid instead of glutamic 
acid in the number 6 position of the B-Chain(7). 
 
 
 3
1.3 Geographic distribution of sickle cell anaemia: 
 Sickle cell anaemia is the most common of all the 
abnormal hemoglobins.  It is found particularly in equatorial 
Africa in abroad zone extending from coast to coast but the 
highest incidence occurs in the eastern part of the continent, 
 where 40-50% of the members of certain tribes are 
affected(8). 
1.4 Sickle cell disease in the Sudan: 
 Sickle cell disease was first reported in the Sudan by 
Archibald in 1926(9); further studies have shown that there are 
three foci of the disease in the Sudan.  In the south, among 
southern Nilotics (up to 18%)(10), in the west, among the 
Misseria tribes (up to 30%)(11),  and in central Sudan in the 
blue Nile province (up to 16%), among immigrants from 
western Sudan and west Africa(11). 
1.5 Malaria and Sickle Cell Anaemia: 
 The sickle cell gene appears to provide some protection 
to children against cerebral falciparum malaria.  The gene 
frequency usually varies directly with the incidence of 
falciparum malaria(3,4). 
 4
 Large-scale population surveys of globin DNA 
polymorphisms and their linkages indicate that, this mutation 
developed independently and spontaneously in at least two 
separate locations(15). 
 Studies were done to describe the physiologic basis for 
the influence of falciparum malaria on the sickle gene which is 
called balanced polymorphism.  The suggestion was that Hbs 
may be poorly metabolized by the parasite(16), and that infected 
cells are more easily sickle and removed from the 
circulation(17,18). 
1.6 Pathogenesis of Sickle Cell Anaemia: 
 The discovery that sickle cell hemoglobin ( 2β2s) has an 
abnormal electrophoretic mobility prompted Linus Pauling and 
his colleagues to categorize sickle cell anaemia as molecular 
disease(4). 
 1.6.1    Molecular pathogenesis: 
 The packaging of very high concentrations of 
hemoglobin (32 to 34 g per deciliter) into red cells requires 
that the protein be extraordinarily soluble.  When sickle 
hemoglobin (Hbs) is deoxygenated, results in a hydrophobic 
 5
interaction with another hemoglobin molecule, triggering an 
aggregation into large polymers.  The polymerization of 
deoxygenated Hbs is the primary event in the molecular 
pathogenesis of sickle cell disease, resulting in a distortion of 
the shape of the red cell and a marked decrease in its 
deformability.  These rigid cells are responsible for the vaso-
occlusive phenomena that are the hall mark of the disease(19).  
When cells containing Hbs deoxygenated, they assume a 
variety of interesting shapes.  In cells with a banana or sickle 
shape, transmission electron microscopy reveals the presence 
of bundles of Hbs fibres point in the direction of each 
projection.  The fiber’s three dimensional structure has been 
elucidated by high resolution electron microscopy and novel 
methods at image reconstruction(20). 
 When a concentrated solution of deoxygenated Hbs is 
examined with the use of various physical and chemical 
probes, large polymers and free tetramers are readily 
demonstrated, whereas species of intermediate size can not be 
detected.  This phenomenon indicates that polymerization of 
 6
Hbs is extremely co-operative and can be regarded as a simple 
crystal solution equilibrium(21).  
 The solubility of a mixture of equal amounts of Hbs and 
HbF is about twice that of Hbs alone.  HbF inhibits 
polymerization, primarily owing to the glutamine residue, 
which prevents a critical lateral contact in the double strand of 
the sickle fibre(22). 
 1.6.2    Kinetics of hemoglobins polymerization 
 The polymerization of sickle hemoglobin is 
hemodynamic events.  The kinetic features of polymerization 
are critical determinants of the shape and morphology (23,24). 
 When deoxygenation is rapid, multiple, independent 
polymerization events results in a granular of cobblestone 
texture that does not alter the cells disk-like shape.  In 
contrast, when SS red cells are slowly or partially 
deoxygenated, a single nucleus of aggregated molecules of 
deoxygenated Hbs is formed.  This nucleation is followed by 
the growth and alignment of fibers, transforming the cell into 
classic sickle shape. 
 7
 The distortion of the shape of the cell by projections of 
aligned Hbs fibers has a critical role in perturbing the 
structure and function of the membrane in SS red cell, 
mediated in part by oxidant stress(25). 
 The rate and extent of polymer formation in circulating 
SS had cells depend primarily on the independent variables: 
 The cell’s degree of dexoygenation, the intracellular 
hemoglobin concentration, and the presence or absence of 
hemoglobin F.  the lag period required for the concerted 
formation of polymer is designated as the delay time (Td).  
Because the range of transit times in the micro-circulation is 
short in relation to the range delay times for S S red cells.  
Polymers do not form in most of the cells cover 8%(23). During 
their flow through arterioles and capillaries this presumably 
the situation in the myocardium, in which sickling and 
infarction do not occur despite the high oxygen. 
 Extraction because of the extremely short transmit time, 
patients who become hypoxic, acidolic, dehydrated and febrile 
are likely to experience vaso-occlusive episodes because these 
factors shorten the delay time(7). 
 8
 1.6.3     Dysregulation of red cell volume: 
 Although the mean intracellular hemoglobin 
concentration and the mean density of the overall population 
of SS red cells are close to those of normal red cells, the 
density distribution of SS red cells is usually broad.  The 
increase in the least dense SS cells is due primarily to high 
number of reticulocytes with relatively low intracellular 
hemoglobin concentration.   
 The presence of substantial population of very dense 
cells is the result of polymerization – induced membrane 
damage leading to enhanced dehydration.  The final stage of 
this process is the irreversibly sickled cell; one that has 
elongated shape even though it has been fully oxygenated and 
lacks polymers.  Since the rate of polymerization of 
deoxygenated Hbs is dependent on hemoglobin 
concentration(26), dense SS cells are much more likely to 
become distored and rigid and thus contribute disproportion 
to the vaso-occlusive and hemolytic aspects of the disease.  
This accelerated in vivo dehydration is the most relevant 
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pathophysiologic consequence of the membrane lesion in SS 
red cells. 
 The most important contributors to the dehydration of 
SS red cells are potassium chloride co-transport and Ca++ 
activated ICT efflux (27).  The rates of potassium chloride co-
transport are much higher in red cells (28), this appears to have 
a major role in the marked dehydration of SS erythrocytes 
resulting in a common and prominent morphologic feature 
target cells. 
1.6.4 Interaction of SS Red Cell and 
Vascular Endothelium 
Measurements performed under both static (29), and 
dynamic (30) conditions have demonstrated that SS red cells 
have a sticky surface and attack more readily than normal 
cells to monolayer of cultured endothelial cells.  The degree of 
adherence is strongly correlated with the severity of the 
disease in patients with SS disease (31). 
Reticulocytes, especially those from patients with SS 
disease, have on their surface the intearin complex 4β1 which 
binds to both fibrinoectin (31) and vascular cell adhesion 
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molecule (33,34), a molecule expressed on the surface of 
endothelial cells, particularly after activation by inflammatory 
cytokines such as tumor necrosis factor . 
In addition, both micro-vascular endothelial cells and 
subpopulation of sickle reticulocytes have CD36, which binds 
to thrombospond in secreted by activated platelets(36,37).  
Several other plasma proteins, including very high molecular 
weight forms of von Willebrand Factor(37),  may make an 
important contribution to adhesion.  During inflammatory 
stress, the adhesion of red cells  to endothelial cells may be 
increased as a result of increased in the above-mentioned 
plasma proteins. 
 
1.7 Clinical Manifestation of SCD: 
 The clinical manifestations of SCD are eventually 
variable.  The newborn infant is protected by the high level of 
fetal hemoglobin, during the first 8 to 10 weeks of life.  As the 
level declines the clinical manifestations appear, and the 
hematological manifestations of sickle cell disease are 
apparent by 10 to 12 weeks of age(38).  
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 Many patients of SCA are reasonably in good health 
much of the time, this state of well being is interrupted by 
crisis.  Diggs(39) defined crisis as “any new syndrome that 
develops rapidly in patients with sickle cell disease due to the 
inherited abnormality”. 
 1.7.1    Vaso-Occlusive Crisis: 
 The vaso-occlusive crisis is one of its most characteristic 
manifestations and consists of pain in the extremities, back 
abdomen or chest.  The frequency, location, duration severity 
and character of pain differ both within and among patients(40). 
 The vaso-occlusive crisis results from complex 
interactions between endothelium, plasma factors, leukocytes 
and rigid, sickled red cells leading to the obstruction of blood 
vessels.  Tissue hypoxia occurs and ultimately leads to tissue 
death and local pain.  Pain episodes managed at home are 
more frequent than those resulting in acute care 
management(41). 
 Vaso-occlusive crisis may affect any tissue, but the pain 
occurs especially in bones (Hand Foot syndrome).  Chest 
(Acute Chest syndrome, Penis (priapsim), and in the 
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abdomen(42).  Infarction  in the spleen, which may be a cause 
of abdominal pain, are so common in sickle cell anemia, that 
after age of 6 to 8 years the spleen usually become very small 
because of scarring “autosplenorectomy” (38). 
 Myonecrosis is unusual but has been documented.  
Vaso-occlusion of cerebral vessels, leading to stroke is the 
most serious type of vaso-occlusive complications(44). 
 
 1.7.2     A plastic crisis: 
 A plastic crisis of sickle cell disease is a sudden 
cessation of bone marrow activity manifested by absence of 
reticulocytes from the peripheral blood and rapidly falling 
hemoglobin level(45). 
 Usually this crisis associated with infections, parvovirus 
B19 appear to be the most important cause of such crisis(46,48) 
and may be accompanied by extensive marrow necrosis(49,50).  
Recovery always occurs after 7-10 days. 
 1.7.3     Sequestration crisis: 
 Sequestration crisis is one of leading causes of death in 
children with SCA(51).   It occurs particularly in infants and 
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young children.  It is characterized by sudden massive pooling 
of red cells, especially in the spleen.  Hypovolemic shock, 
cardiovascular failure and massive splenomegaly may develop 
rapidly(52). 
 1.7.4     Hemolytic crisis: 
 Hemolytic crisis is the commonest type of anaemic 
crisises(53) in children with SCA. 
 It is characterized by decreased level of haemoglobin, 
and increased level of reticulocytes, unconjugated serum 
bilirubin concentrations, and the presence of nucleated red 
blood cells are also increased. 
 1.7.5     Acute multiorgan failure: 
 Acute multiorgan failure is a life threading complicating  
of SCD, which can exhibit without any evidence of chronic 
organ damage and is easily reversed by prompt and aggressive 
transfusion therapy(54). 
 Most episodes occurred during vaso-occlusive crisis, 
which was associated with a sever pain event. The onset of 
organ failure was associated with fever, rapid fall in 
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haematocrit, platelet count and altered sensorium, later 
respiratory, renal and hepatic failure set in. 
1.7.6 Chronic organ damage in SCA: 
1.7.6.1      Growth 
Although the birth weight of babies with SCA is 
normal(55), by 4606 month of age their weight remains 
consistently lower than normal(56-58).  Height may be sub-
normal in children and young adolescents but normal or 
greater than normal in late adolescents and adults(59). 
The exact reasons for poor growth have not been 
established, increased calorie and protein needs and 
deficiencies in zinc, folic acid and vitamins A, C and E may be 
factors. 
Onset of puberty is delayed, with normal bone age in 
children under 4 years of age(60) and delayed bone age in 
children 12 to 19 years of age(57). 
Transiently impaired gonadal function has been 
demonstrated(61), and may explain the delayed sexual 
maturity.  In Africa, delayed maturity may be corrected by folic 
acid supplementation(62). 
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1.7.6.2 The cardiovascular system in sickle cell 
disease: 
Sickle cell anaemia is more severe than other anaemias 
of comparable intensity as, due to the sickling process, these 
patients appear to be at the upper limit of physiological 
compensatory mechanisms usually encountered in chronic 
anaemia(63). 
The majority of patients with SCA demonstrate some 
abnormalities on cardiovascular examination(64),  although in 
many cases this appears to reflect circulatory adjustment to 
chronic anaemia rather than cardiac abnormality.  So, sings of 
hyperdynamic circulatory state such as tachycardia, widend 
pulse pressure, active pericardium impulse and laterally 
displaced prominent apex usually found(64). 
Accentuation of the pulmonary component is common 
and does not seem to correlate with the presence of pulmonary 
hypertension(65).  Systolic murmurs are very common and may 
be ejection in type, commonly pansystolic(64,66-69). 
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1.7.6.3      The kidneys: 
Renal abnormalities in sickle cell disease include, 
impaired urinary concentration ability, renal acidification, 
hematuria, potassium secretion, proteinuria, nephritic 
syndrome, chronic progressive renal failure, acute renal failure 
and end-stage renal disease(70). 
1.7.6.4 Gastrointestinal tract: 
Gastrointestinal pathology in sickle cell disease involves 
acute pancreatitis(71,72),  chole and choledocholithiasis(70) and 
hepatic dysfunction due to the intrahepatic sickling of 
erythrocytes(73), and transfusion-related hepatitis(74). 
1.7.6.5     The eyes 
Tortuosity and sacculation of the conjunctival vessels 
are seen in more than 90 percent with SCD.  They are best 
seen in the lower temporal area, disappear after exchange 
transfusion. They are no deleterious effect on the eye(75). 
Non proliferative retinopathy requires no therapy.  The 
more serious complication is proliferative retinopathy, for 
which laser therapy has been advocated, and is currently 
under evaluation(76). 
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1.7.6.6 The skeleton: 
Skeletal changes in SCD are common, and are due to 
expansion of the marrow cavity and repeated bone infarction. 
Vertebrae are generally Flattened with characteristic 
biconcare deformity called codfish vertebrae”.  Repeated 
infarctions leads to aseptic necrosis of the femoral head, which 
may respond to strict bed rest but may necessitate total hip 
replacement(77). 
 
1.7.6.7    Neuro Psychological aspects 
The central nervous system involvement in SCD ranges 
from overt strokes(78) to silent infarct which is defined as an 
MRI finding of increased signal intensity on T2 imaging in a 
patient without a history of stroke(79).  School aged children 
with sickle cell disease had compromised neuropsychologic 
function in the presence of silent infarcts(79). 
1.7.6.8    Auditory function: 
As part of central nervious system involvement, the 
peripheral and central auditory dysfunction can occur in 
patients with SCD(80). 
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1.7.6.9 Pulmonary involvement: 
The lung is among the major organs involved in SCD(81-
83).  The pulmonary manifestations of SCD are both acute and 
chronic.  They remain the leading cause of morbidity and 
mortality in patients with SCD. 
Clinical lung involvement commonly takes two major 
forms:   
The acute chest syndrome (ACS) and sickle cell chronic 
lung disease (SCCLD) (81-83).  More than 20% of adults with 
SCD have fatal pulmonary complications(84). 
I-   Airway hyper-reactivity: 
Air way hyper-reactivity is a common pulmonary 
function test abnormality among young subjects with SCD(85-
87). 
The reported incidence of obstructive lung defects in 
children with SCD is 35% to 37%(85,86). 
A prospective controlled trial demonstrated air way 
reactivity to cold air in 60% patients with SCD compared with 
 19
none in the control population, suggesting an association 
between SCD and airway reactivity(87). 
The pathogenesis of increased airways reactivity and its 
relationship to ACS and SCC LD, however, is unknown. 
II-    Oxyhaemoglobin desaturation 
Nocturnal oxyhaemoglobin desaturation has been 
reported in SCD subjects with a prevalence of up to 40% in 
children and adolescents(88,89). 
Proposed mechanisms are obstructive sleep apnoea, 
intrinsic lung disease, and an abnormality in oxyhaemoglobin 
affinity(90).  Several investigators documented obstructive sleep 
apnoea in SCD with or without nocturnal oxyhaemoglobin 
desaturation(91-93). 
Although it has been shown that how nocturnal oxygen 
saturation is associated with higher rate of painful crisis in 
childhood, the relationship between nocturnal oxyhaemoglobin 
desaturation and vaso-occlusive crisis or ACS is poorly 
understand(94). 
Hypoxia in SCA is associated with history of recurrent 
chest infection(95). 
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III- Thromboembolism: 
Patients with SCD are known to be hyper-
cogulable(94,96,97).  A variety of mechanisms are postulated from 
low levels of protein S and C to raised level of tissue factor and 
factor III, and to enhanced platelet reactivity, as well as to 
generation of hydroxyl radiacls and liberation of fibronectin 
and thrombospondin(98-102).  Pulmonary thromboembolism may 
contribute to both ACS and SCCLD(97-103). 
Although thromboembolism has been noted in 8% to 
25% of necropsy studies in patients with SCD, the exact 
incidence and prevalence is unknown(81-82). 
IV-   Acute chest syndrome 
ACS is defined as the appearance of a new pulmonary 
infiltrate on chest radiograph, accompanied by fever and a 
combination of respiratory symptoms that include cough, 
tachypnoea, and chest pain(104-108). 
It is the second most common cause of hospitalization in 
patients with SCD and responsible for up tp 25% of deaths(84-
107).  ACS has been reported to occur in 15% to 43% of patients 
with SCD.  Moreover, recurred episodes occur in up to 80% of 
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those who have had a prior episode(107-109).  ASC rates vary 
directly with steady state leucocyte counts, haemoglobin 
concentration and inversely, with age and haemoglobin F 
levels(107). 
There is also strong correlation between ACS and the 
occurrence of neurological complications(106-108). 
The aetiology of ACS is usually vaso-occlusion, infection 
or both(108).  Other causes includes: 
Pulmonary fat embolism(109-111).  In situ thrombosis(97), 
hypoventilation from pain and/or narcotic analgesics(112-114) 
and iatrogenic pulmonary oedema(115,116). 
(V) Sickle cell chronic lung disease (SCCLD): 
The exact incidence, prevalence, natural history, and 
methods of diagnosis of SCCLD have not been established due 
to the lack of detailed epidemiological studies.  It is suggested 
that SCCLD has a prevalence of approximately 4% in patients 
with SCD(83,117).  SCCLD is presumably related to recurring 
episodes of infarction and infection and is characterized by: 
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i- Radiographic Abnormalities: 
Significant radiographic interstitial lung disease has 
been seen in patients with SCD(83,118).  In a prospective study, 
41% patients with SCD who had at least one prior episode of 
ACS were found to have significant multifocal interstitial lung 
abnormalities on thin section computed tomography scans of 
the chest.  A correlation was found between the severity and 
extent of interstitial abnormalities on computed tomography 
and the number of prior episodes of ACS(118). 
A correlation was found between the severity and extent 
of interstitial abnormalities on computed tomography and the 
number of prior episodes of ACS(118). 
II- Pulmonary function abnormalities: 
Pulmonary function abnormalities in SCA are frequent 
and are characterized by airway obstruction, restrictive lung 
disease, abnormal diffusion capacity, and hypoxaemia(83,86,95, 
119-121). 
However, a restrictive airways abnormality is typically 
seen in patients with SCCLD(83,86,11-121). 
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Santoli and Co-workers measured pulmonary function in 49 
patients with sickle cell anaemia and found that 37% of the 
patients had obstructive lung disease, defined by a ratio of the 
forced expiratory volume in Is to the forced vital capacity 
EFVI/FVC) < 80% of predicted with normal total lung capacity.  
Twenty percent of these patients had mixed obstructive and 
restrictive pulmonary function, and 20% had restrictive 
defects alone(86). 
  In a restrospective analysis of 63 chidlren with sickle 
cell disease, lung function was evaluated with maximal 
respiratory flow-volume cures and body plethysmography, 
lower air way obstruction was found in 35% and restrictive 
lung disease in 8%.  Positive response to bronchodilator was 
documented in 78% in those with LAO, and 67% of those with 
restrictive lung disease, and the conclusion was, obstructive 
lung disease possibly proceed the development of restrictive 
lung disease, and air way reactivity may be part of the 
pathogenic mechanism. 
 A case-controlled study was done by Paul Pianosi and 
co-worker, he found that children with sickle cell disease, 
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particularly those with Hb SS, have lower static and dynamic 
lung volumes and flow rates than do age-sex, and race 
matched control subjects, either a restrictive or obstructive 
pattern may be seen (122). 
 Another case-controlled studied 64 children with sickle 
cell disease and 64 ethnic matched controls, the results 
suggest that restrictive abnormalities may become more 
prominent with increasing age and that lung function differs 
significantly in children with SCD compared with ethnic 
matched controls of a similar age (123). 
 Hijazi Z and Co-workers studied the pulmonary function 
in Kuwaiti children with sickle cell disease, this study revealed 
and early restrictive and obstructive pulmonary function 
pattern in steady state children with sickle cell disease and 
there was no significance in the pulmonary function test 
parameters between patients with history of Acute Chest 
Syndrome and those without – Although patients with 
frequent vaso-occlusive crisis had lower pulmonary function 
test parameters than those without (124). 
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 Also pulmonary function was studied in Tunisian 
children with sickle cell anaemia where 2/3 of the patients 
was found to have restrictive pattern (125). 
 Restrictive and obstructive pulmonary function was also 
found in Nigerian children with sickle cell anaemia (126). 
 A number of studies suggest that asthma is a significant 
comobidity in patients with sickle cell anaemia, in one of the 
controlled studies, Leong and Stark evaluated 40 patients with 
sickle cell disease and 10 sibling control subjects.  They found 
that approximately 60% of the patients with sickle cell disease 
had air way reactivity (to cold air challenge) where as none of 
the control subjects had reactive air ways (127). 
 Also, some studies suggest that children with sickle cell 
anaemia who have asthma, had an increase incidence of 
repeated attack of acute chest syndrome (128,129). 
 Peak expiratory flow rate (PEFR) was studied in 20 
matched pairs of children with homozygous sickle cell disease 
with either no episodes of six or more episodes of acute chest 
syndrome, a highly significant reduction in PEFR was 
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observed in children with multiple episodes of acute chest 
syndrome (130). 
 Also ventilation perfusion defects (131), secondary to the 
pulmonary edema which may results from overhydration in an 
effort to prevent further sickling in patients with sickle cell 
crisis. 
III-  Pulmonary hypertension: 
Pulmonary hypertension is a common complication of 
sickle cell anaemia.  In spite f the mild elevations in 
pulmonary artery pressures in these patients, the associated 
morbidity and mortality is high. 
The aetiology of pulmonary hypertension is probably 
multifactorial, including haemolysis, impaired nitric oxide 
bioavailability, chronic hypoxaemia, thromboembolism, 
parenchymal and vascular injury because of sequestration of 
sickle erythrocytes, chronic liver disease and asplenia(132).  
1.7.6.10    Infections in sickle cell Anaemia: 
Infection is the most common of death in children with 
SCA(133,134). 
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The increase in incidence aid severity of infection in 
patients with SCA is related to the defects in host immunity. 
Infection may present in its sever form by septic shock, 
bactermia, or 95 causative factor of Acute Chest Syndrome 
especially in the young child(135).  In one study(136) Mycoplasma 
pneumoniae and Chlamydia were found in 16% of patients 
with ACS, and mycoplasma horminis was found in 10% of 
patients with ACS(136). 
I-  The spleen: 
The spleen normally serve two separate immunologic 
functions: 
(1) Clearance of particulate matter 
from the intravascular space. 
(2) Antibody synthesis 
Both functions are impaired in SCA.  During the first 
year of life, despite palpable splenomegaly, patients with SCA 
have functional asplenia.  The inability to clear particulate 
matter from the blood, (137,138) and they are susceptible to the 
most serious infectious complication of asplenia – 
pneumococcal sepsis(139). 
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These children do respond normally to intramuscularly 
administrated antigen, such as pneumococcal vaccine(134). 
After five years of age and due to the repeated 
infarctions, the spleen will be very small and loss its function 
which is called auto-splenectomy. 
II-  Serum factors: 
Levels of serum innumoglobulins are normal or 
increased in children with SCA(140).  However, the serum is 
deficient in heat – liable opsonizing activity, related to an 
abnormality of the properdin pathway.  Which is specific for 
the phagocytosis of pneumococci(141-142.). 
III-  The white blood cells: 
 Boggs and Co-workers have demonstrated that chronic 
leukocytosis of SCA is a reflection of shift of granulocytes from 
the marginating to the circulating poor (with a high 
granulocytes turnover(143). 
Oxidative metabolism of the granulocytes has been 
reported as abnormal, but this has not been confirmed in 
more studies. (144). 
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1.8.1    Diagnosis of sickle cell disease: 
 Diagnosis of SCD depends upon documentation of the 
presence of sickle hemoglobin, preferably by 
electrophoresis(145). 
 I-  Sickling Test: 
 Is a simple rapid method that includes the observation 
of sickling of red cells containing sickle hemoglobin 
microscopically under cover slip by suspending the cells in a 
droplet of 2% solution of sodium metabisulfate(146). 
 II-  Solubility Test: 
 This test depends on the low solubility of reduced sickle 
hemoglobin which results in the development of turbidity after 
diluting the blood in normal saline(147).  It has the advantage of 
differentiating heterozygous from homozygous sickle cell 
carriers. 
 
 III-  Hemoglobin Electrophoresis: 
 Hemoglobin electropohoresis using alkaline buffer on 
cellulose acetate paper is a reliable test for diagnosis of 
SCD(145). 
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 Sickle cell anaemia can be diagnosed at birth by 
subjecting cord blood sample to electrophoresis.   
 IV-  DNA analysis 
 Chrorionic villus bopospy has been used extensively to 
obtain fetal DNA for the diagnosis in the first trimester(148). 
 
1.8.2   Investigation For Pulmonary Involvement in 
SCA: 
   (1)    Radiographic Investigation: 
           (1-a)    Chest X-ray: 
  New pulmonary infiltrate on chest X-ray in 
addition to the clinical feature will help in the diagnosis of 
ACS(104). 
 (1-b)     Computed tomography scan: 
 Computed tomography scan to detect interstitial lung 
disease which may be seen in patients with SCA(83,118). 
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     (2)  Oxygen Saturation: 
 Oxygen saturation measured by arterial blood gas 
analysis or most practically by pulse oxiometry, is found to be 
low in children with SCA especially at night, with prevalence of 
up to 40% in children and adolescents with SCA(88,89). 
 
(3)   Bronchoscopy: 
 Bronchoscopy may be considered in patients with ACS 
for more accurate diagnosis of the episode(81,108). 
 
(4) Pulmonary function tests: 
  
 Pulmonary function tests can be used to diagnosed 
obstructive, restrictive or both and to measure lung-diffusing 
capacity for carbon monoxide, which were impaired in many 
patients with SCA (119-121). 
 
(5) Echocardiography:  To measure the pulmonary artery 
pressure  
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1.9     Management of Patients with Sickle Cell 
Anaemia. 
1- General Measures: 
 Since no fully satisfactory, specific treatment for SCA 
have yet become available, physicians must concentrate their 
therapeutic efforts in the direction of continuous and effective 
general medical care and appropriate management of 
complications (149-150). 
 The chances of having children with SCA and the 
feasibility of antenatal diagnosis should be clearly explained to 
couples at risk (151). 
 Early in life, when the risk of infection is highest, 
counseling parents about the importance of immunizations 
and penicillin prophylaxis, the detection of enlarging spleen, 
and the dangers of fever and increasing pallor may be life 
saving (151-153).  One study found an 94% reduction in 
pneumococcal sepsis among children given 125 mg of 
penicillin prophylactically twice daily from three months to 
three years of age. 
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 Followed by 250 mg twice daily until five years of life 
(152).  Patients with SCA should be also vaccinated against 
hepatitis B, and haemophilus influenzae. 
Also to stress the liberal amount of fluids to take 
regularly and to increase the amount if there is increase losses 
for example vomiting or diarrhoea, because dehydration 
increases the risk of thrombosis and cerebrovascular 
accidents. 
II- Management of patients with crisis: 
Painful crisis: 
 To control the pain is very important in painful crisis.  
Paracetamol alleviates pain in most patients.  In severe cases 
stronger analgesics may be needed.  Potentially addicting 
analgesics may be rarely required like pethidine and morphine 
(154,155). 
 To keep patient warm and rehydrated is very important. 
 III-  Blood transfusion: 
     (A)   Indications for blood transfusion include 
(151,156,157): 
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? Hemoglobin concentration less than 6 
g/dl. 
? Evidence of acute hemolysis 
? Sequestration crisis. 
? Cerebro-vascular accident 
? Acute chest syndrome 
? Priapism 
? Aplastic crisis 
 
(B)   Partial exchange transfusion (151): 
  It is aimed to reduce the patients total abnormal 
hemoglobin to about 40% indication for partial exchange 
transfusion are: 
- Cerebro-vascular accident (CVA) 
- Sever priapism 
- Sever hematouria 
- Sever epistaxis 
- In preparation for major surgery 
(C) Hyper –transfusion therapy: 
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Hyper-transfusion therapy means giving blood at regular 
interval e.g. every month. 
In one study, thirteen children with SCA (aged 1.9 – 
14.8 years) underwent echo-cardiographic assessment of 
cardiac status while on and off periodic-hyper-transfusion 
therapy.  Two to three units of washed packed RBCs were 
transfused every 2-4 weeks for 24 months, resulted in 
normalization of left heart chamber enlargement and 
statistically significant deceases in heart rate.  Left ventricular 
function parameter remained normal on and off transfusion 
therapy.  Changes in left ventricular diastolic dimension and 
cardiac output correlated with changes in     % of Hbs, Hb 
concentration(158). 
(IV) Hydroxy urea: 
High HbF concentrations reduce the severity of sickle 
cell anaemia by preventing the formation of Hbs polymers(151). 
Hydroxyl urea was thought to act solely by increasing 
Hbs concentration(159,160,161).  But further studies suggested 
that the related reduction in neutrophils, monocytes and 
reticulocytes may also be clinically important.  Hydroxyurea 
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also raises the total hemoglobin concentration slightly(167).  The 
incidence of acute chest syndrome is significantly reduced in 
adult patients treated with hydroxyurea(163-164).  A double 
blind, placebo controlled trial of 299 adults with sickle cell 
disease was terminated early, because hydroxyurea reduced 
the frequency of acute chest syndrome hospitalization, and 
need for transfusion(164).  Therefore it should be considered in 
patients with recurrent episodes of acute chest syndrome. 
(V) Management of pulmonary complication: 
 In addition to the above management children with 
pulmonary complication needs extra management: 
(A) Acute Chest Syndrome: 
(1) General measures: 
Sickle cell disease patients admitted for painful crisis 
should be considered in the prodromal phase of acute chest 
syndrome. Prophylactic manoeuvres like close pulmonary 
monitering, cautious hydration, optimal pain control, and 
incentive spirometry remain essential components of therapy.  
Vigorous hydration may result in pulmonary oedema and 
worsening respiratory distress and should be avoided(165).  
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Judicious use of analgesics is necessary to relieve bone pain 
and splinting to prevent lung a telectesis.  If there is no 
contraindication, non-steroidal agents should be the part of all 
pain control regimens as they have anarcotic-sparing effect.  
Efficacy of incentive spirometry in preventing the 
pulmonary complications ( a telectasis and in filtrates) 
associated with the ACS has been proven in a randomized 
controlled trial and should be routinely used in patients with 
SCD(114), 
? Oxygen therapy: 
Oxygen should be administered for the correction of 
hypoxia, which if untreated creates a risk of multiorgan 
failure(111). 
? Antibiotics: 
Broad spectrum antibiotics, including amacrolide 
orquinolone in view of atypical infections, such as Chlamydia 
and mycoplasma should be administered(81). 
? Bronchodilators: 
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Bronchodilators are given to patients when airflow 
obstruction is present, though some investigators recommend 
their routine use in all patients(108).  
Many patients with sickle cell anaemia have airway 
hyper-reactivity and this fact should be considered when 
managing these patients on the ventricular to prevent 
autopositive end expiratory pressure and dynamic hyper 
infiltration (108).  
? Bronchoscopy: 
Bronchoscopy may be considered in patients not 
responding to initial therapy.  It can be utilized as an airway 
clearance technique by removing the thick and tenacious 
airway secretions often found in patients with Acute Chest 
Syndrome(81,108). 
? Hydroxyurea: 
? Corticosteroids 
A short course of corticosteroids has been shown to 
reduce the need for blood transfusion and the length of 
hospitalization in children with Acute Chest Syndrome(166) . 
? Nitric oxide: 
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Nitric oxide may be beneficial in sever (167,168) cases that 
are refractory to standard therapy.  There are isolated reports 
of significant reduction in pulmonary artery pressure, 
pulmonary vascular resistance, and alveolar-arterial gradient 
with concomitant improvement in cardiac output in patients 
with Acute Chest Syndrome after the inhalation of nitric oxide 
(167,168). 
 
(B) Pulmonary hypertension 
Management of pulmonary hypertension related to sickle 
cell disease include: 
? Pulmonary vasodilator 
Therapeutic nitric oxide inhalation may prove efficacious 
in patients with sickle cell disease and secondary pulmonary 
hypertension due to its to selectively dilate the pulmonary 
vasculature which reduces pulmonary pressure and increases 
oxygenation (169,170). 
? Hydroxyurea & oxygen therapy 
? Anticoagulation 
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A retrospective and a non-randomized prospective study 
suggested that anticoagulation increases survival in patients 
with primary pulmonary hypertension (171,172).  Chronic 
anticoagulation therapy is, therefore, recommended in sickle 
cell disease with pulmonary hypertension unless a 
contraindications is present. 
? Surgical management: 
The role of atrial septostomy or single or bilateral lung 
and heart lung transplantation in patients with pulmonary 
hypertension related to sickle cell disease is not known (172). 
 
VI- Bone Marrow Transplantation: 
 Bone marrow transplantation (BMY) as a treatment of 
sickle cell anaemia was first used in Europe for patients from 
Africa.  On the assumption that the risks of disease in their 
countries of origin justified hazards of transplantation (173). 
 These patients did well and since then additional 
patients have undergone transplantation in Europe and 
United State (174,175).  Children and adolescents younger than 
16 years of age who have sever complications, and have HLA – 
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matched donor available are the best candidates for bone 
marrow transplantation. 
 More than 90% of patients with sickle cell anaemia who 
undergone bone marrow transplantation (100 patients) 
survived, 70 to 85% had event-free survival, and 15% have 
graft rejection (151,175). 
VII- Gene therapy: 
 Autologous hematopoietic cells have been used as 
targets of gene transfer, with applications in inherited 
disorders, including sickle cell anaemia (176).   In one study (177) 
achimeric  oligonucleotide composed of DNA and modified RNA 
residues was used to direct correction of the mutation I the 
hemoglobin beta Sallele.    After introduction of the chimeric 
molecule into lymphoblastoid cells homozygous for the beta 5 
mutation, there was a detectable level of gene conversion of 
the mutant allele to the normal sequence.  The efficient and 
specific conversion directed by chimeric molecules may hold 
promise as a therapeutic method for the treatment of genetic 
disease. 
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JUSTIFICATION 
 
• Sickle cell anaemia is one of the commonest chronic 
hemolytic anemia in the Sudan; it is a disease with 
high morbidity and mortality. 
• Pulmonary complications accounts for significant 
morbidity and mortality in children with sickle cell 
anaemia. 
• Pulmonary complications of sickle cell anaemia are 
not well studied in Sudanese children. 
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OBJECTIVES 
 
 
 
1) To study the pulmonary function in Sudanese 
children with sickle cell anaemia. 
2) To detect the association between pulmonary 
functions test and the frequency of acute chest 
syndrome and number of sickle cell crises. 
3) To detect the association between pulmonary 
function test and the severity of sickle cell anaemia. 
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Chapter Two 
2-  PATIENTS AND METHODS 
 
 
2.1 Study Design: 
Cross-sectional prospective hospital based study.  
2.2 Study Area: 
Referral clinics in Khartoum Children Emergency 
Hospital, Omdurman Children Teaching Hospital, Soba 
Hospital and Ahmed Gasim Hospital.   
2.3 Duration of the study: 
 Six months since February 2005, according to the time 
frame. 
Time frame: 
Time per months Activity  
1st 2nd 3rd 4th 5th 6th  
Preparation       
Data collection       
Data entry and analysis       
Draft report       
Final report        
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2.4 Study population: 
  All children between 5 years and 18 years in whom the 
diagnosis of sickle cell anemia was confirmed by Hb 
electrophoresis, HbS-S in the steady state. Patients in the 
steady state were defined as subjects who were crisis free for 
at least 2 weeks prior to the study and had not received blood 
transfusion in the preceding 4 months. 
   
2.5 Sample Size: 
According to the equation: 
N = z2pq/d2     
N = Sample size.  
z = Statistical certainty.  
p = Prevalence.  
q = Probability of failure. 
d = Designed margin of error (0.02). 
 
The sample size = 72 
 
2.6 Inclusion Criteria: 
All children between 5 and 18 years who reported to the 
referral clinics in the above mention hospital in whom the 
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diagnosis of sickle cell anemia had been confirmed by 
electrophoresis in the steady state were included in the study. 
2.7 Exclusion Criteria: 
• Children who presented with any type of crisis 
within a period of two weeks from the time of the 
study or who received blood transfusion within a 
period of 4 months prior to the time of the study. 
• Children or whose parents refused to participate in 
the study. 
• Any child with chest deformity. 
• Any child with chest muscle weakness. 
• Any child with chronic lung disease e.g. 
tuberculosis.  
• If the child is not able to co-operate with the Spiro 
meter.   
2.8 Technique: 
2.8.1 Consent: 
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o Informed verbal consent was obtained 
from the parents  or care takers for 
every child included in this study.   
o Informed verbal consent was obtained 
from the consultants in the referred 
clinics. 
2.8.2 Research Team: 
This include the author who selected cases, completed 
the questionnaire, conducted physical examination and 
measurements of PEFR, FVC and FEV1. 
2.8.3 History:  
 History from child and parents included general 
information about age, sex, residence, consanguinity and 
tribe.  Information about fathers and mother’s job, their 
education level and monthly income were also obtained. 
 Parents were inquired about number of crisis, 
hospitalization, past history of acute chest syndrome, (acute 
chest syndrome was defined as any past history of breathless, 
cough, fever and chest pain which was sever enough to 
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nessiate hospital admission), and numbers of blood 
transfusions. 
 The severity of sickle cell anaemia was assessed using 
the severity index(175-177). 
 The severity index was defined as the total number of 
attacks, hospitalizations, crisis, transfusions, symptoms and 
signs per year.  a severity index was calculated for each of the 
patients according to the following parameters. 
 
 
Parameters Score of severity index 
 0 1 2 3 
Crisis/year <1 1-2 3-6 > 6 
Tx/year* 0 1 2-3 > 3 
ASH+ > 10 8 – 10 6-7.9 < 6 
 
* Tx/year  =  number of blood transfusion/year 
+ ASH =  average steady-state hemoglobin g/dl 
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 Any child who scored > 6 was considered as a sever case, 
those with score of 4-5 were considered as moderate cases, 
and those with score of 0 – 3 were considered as mild 
cases(177). 
 
2.8.4 Examination: 
 Every child in the study was subjected to routine clinical 
examination, with especial emphasis on respiratory system 
examination.   
 Increased respiratory rate defined as respiratory rate of 
more than 30/min. 
2.8.5 Investigations: 
 2.8.5.1 Hemoglobin level was done for all children 
included in the study according to the standard methods.  
Hemoglobin was registered with reference to Sudanese 
children normal levels(178). 
2.8.5.2   Measurement:   
? Weight:   
The child was weighted with light dresses and without 
shoes – the weight was measured in kilograms (using seca 
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Sauglingswaage Company Ltd, Germany) and the reading 
taken to the nearest 0-1 kg. the weights were plotted on the 
centile chart. 
 
 
? Height 
This was measured with the child standing straight the 
head straight and facing horizontally with the hand hanging 
by side and lower limb straight with the feet put together and 
without shoes.  Measured in centimeters (using seca 
Sauglingswaage Company Ltd, Germany) and the reading 
taken to the nearest 0-1 cm.  The height was plotted on the 
centile chart. 
 
? Peak Expiratory Flow Rate (PEFR): 
This was measured using the mini Wright peak flow 
meter (Clement Clarke International Ltd. London, England), 
express in litres/minute, the peak expiratory flow rate in the 
fastest rate at which air can move through airway during a 
forced expiration started from fully inflatted lung; the PEFR 
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was taken with the child standing up and holding the peak 
flow meter horizontally.  The child was told to lake a deep 
breath, seal his/her lips round the mouth piece and then blow 
out as fast as hard as possible. 
After the child was familiar with the procedure and has 
successfully performed an example; he/she can blow out the 
peak flow meter three times.  The best of the three reading was 
recorded for each child. 
? Pulmonary function test: was measured 
by spirometry (using microspirometer Clement 
Clarke International Ltd. London, England).  The 
forced vital capacity (F.V.C.) and force expiratory 
volume in one second   (FEV1)  were measured using 
Micro Loop Spirometer.   
The children were taught to take a deep inspiration, and 
to hold the instruments correctly and to expire as fast and 
forceful as possible, the majority of children were taught 
easily.  This was the main difficulty encountered through the 
whole work. 
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Children were tested in the standing position without 
nose clips.  The test was performed between 8-12 am.  The 
results for each child were taken from the test with the 
greatest some of FVC and FEV1, PEFR and will be chosen from 
the two best efforts within 5% of each other. The values of 
FVC, FEV1 and PEFR will be express as percentage of the 
predicted values based on normal values for Sudanese 
children lung functions determined by Dr. Mabrouk study 
1983 by the equation (Y=a+bx), where:  
Y: represent the dependant variable.  
x: the standing height.  
a: is the intercept at the origin with units identical to 
the variables. 
b: is the slope with units equal to those of the 
variables.    
The degree of pulmonary dysfunction was interpreted as 
follows:(179). 
 a) Obstructive airways disease:- 
disproportionate reduction in the FEVI < 80% of 
predicted value as compared to the FVC. 
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b) Restrictive dysfunction:- 
Reduction in the  FVC < 80% of predicted value with 
a normal or elevated FEV1/FVC ratio. 
c) Restrictive and obstructive dysfunction: 
Reduction in both FVC < 80% and FEV1 < 80%. 
        d) PEFR 
                Reduction in the PEFR < 80%. 
e) Normal 
  FVC > 80%, FEV1 > 80% and PEFR > 80%. 
 
2.9 Data analysis and statistics: 
The data obtained was coded and entered into a 
computer and a master sheet was constructed to arrange the 
row data, tables were then drawn and chi square test (X2) was 
used to test for significant differences between the variables 
using the statistical package for social science (SPSS) a P 
value of 0.05 or less is considered significant. 
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Chapter Three 
 
3- RESULTS 
3.1 Socio-Demographic Characteristics of the 
Study Group: 
3.1.1 Age and sex characteristics of the study   
group: 
A total number of 73 patients who were diagnosed as 
having sickle cell anaemia and above five years of old were 
studied as the study group.  Children in the age group from 
5 – 9 years were 35 children, and constituted 47.9% of the 
total number.  Children in the age group > 9 – 13 years were 
21 children constituted 28.7% of the total number.  While 
children in the age group> 13 – 18 years were 17 children 
23.3%.  (Figure 1) 
Regarding sex characteristics of the study population, 
males included in the study were 34 (46.6%) while females 
were 39 (53.4%). (Figure 2) 
 
 
 
 
 55
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 56
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 57
Children who presented from rural areas were 29 
children (39.7%), whose from urban areas were 21 children 
(28.8%), while 23 (31.5%) were from peri-urban areas. 
(Figure 3) 
The majority of the patients 42 (63.6%) were from 
Misseria tribe. 
 
3.2 History: 
3.2.1 Family and social history: 
Thirty three (45%) of the parents were first degree 
relatives, 13 (17.8%) were second degree relatives, 8 (10.9%) 
were distant relatives, while there was no consanguinity 
between the parents of 19 (26.0%) children as shown in 
(Figure 4). 
Regarding the number of sibs of the patients; 51 
(69.9%) of the patients had 0-3 sibs 19 (26%) of the patients 
had 4-6 sibs while only 3 (4.1%) patients had more than 6 
sibs. (Table 1) 
Thirty five of the sibs of the patients 47.9% had sickle 
cell anaemia, while 38 (52.1%) of the sibs had no similar 
condition. (Figure 5) 
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Table (1):  Number of Sibs of cases of SS among study 
group  
n = 73 
Number of sibs No Percentage (%) 
0 – 3 51 69.9 
4 – 6 19 26.0 
> 6 3   4.1 
Total 73 100.0 
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The educational level of the parents varied from low to 
high in both sides; 28 (38.4%) of fathers were illiterates; 22 
(30.1%) of them had primary education; 18 (24.7%) had 
secondary education; while only 5 (6.80%) of them had 
university education. (Table 2) 
Regarding the educational level of the mothers, 31 
(42.5%) of the mothers were illiterates, 28 (38.4%) of them 
had primary education, 12 (16.4%) of the mothers had 
secondary education, while only 2 (2.7%) of the mothers had 
university education.  Neither of the fathers nor the mothers 
had post graduate education. (Table 2) 
Regarding parents’ occupation; 4 (5.5%) fathers 
running small business; one of them (1.4%) was 
professional, 12 (16.4%) were employee, 21 (28.8%) were 
skilled labourer, 23 (31.5%) were unskilled labourer, 6 
(8.2%) were either unemployed or retired, 6 (8.2%) were 
died. (Table 3) 
The majority of the mothers 63 (86.3%) were house 
wives. (Table 3) 
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Table (2):  Parent’s educational Level of study group 
Education 
level 
 
Father 
 
Mother 
 No % No % 
Illiterate  28 38.4 31 42.5 
Primary 22 30.1 28 38.4 
Secondary 18 24.7 12 16.4 
University 5 6.8 2 2.7 
Post graduate 0 0 0 0 
Total 73 100 73 100.0 
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Table (3):  Parent’s occupation of study group 
Occupation  Father Mother 
 No % No % 
Running small 
business 
4 5.5 5  6.8 
Professional 1 1.4 1  1.4 
Employee 12 16.4 2  2.7 
Skilled labourer 21 28.8 2  2.7 
Unskilled labourer 23 31.5 0  0.0 
Housewives, retired 6 8.2 63 86.3 
Died 6 8.2 0 0.0 
Total 73 100 73 100 
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 The majority of the families 57 (78.1%) had a low 
income; 14 (19.2%) had moderate income, while only 2 
(2.7%) of them had high income. (Table 4) 
 Regarding children’s education among the study 
group, 15 (20.5%) children had no schooling.  However the 
majority of children 58 (79.5%) had schooling.  Among 
children who had schooling 17 (23.3%) had regular school 
attendance, while 21 (28.8%) had irregular school 
attendance and 20 (27.4%) repeat a year. (Table 5) 
 School performance of 11 (19%) children was 
excellent, 29 (50%) had good school performance, average 
school performance was encountered in 15 (25.9%), while 
poor school performance was found in only 3 (5.2%) of 
them. (Table 6) 
 Regarding the vaccination of children in the study, 
the majority of the patients 66 (90.4%) were vaccinated up 
to date, 5 (6.8%) had incomplete vaccination, while only 2 
(2.7%) were not vaccinated at all. (Figure 6) 
 Two (2.7%) children only had both pneumococcal 
vaccine and hepatitis B vaccine.  None of the patients were 
vaccinated against haemophilus influenzae infection. 
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Table (4):  Income of families of study group 
 
Status No % 
   
High 2 2.7 
Moderate 14 19.2 
Low 57 78.1 
Total 73 100.0 
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Table (5):  Educational level of study group 
Status No % 
   
Regular 17 23.3 
Irregular 21 28.8 
Not at school 15 20.5 
Repeat year 20 27.4 
Total 73 100 
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Table (6):  School performance of study group* 
n = 58 
Status No % 
Excellent 11 19.0 
Good 29 50.0 
Average 15 25.9 
Poor 3 5.1 
Total 58 100 
 
 
* NB: 15 children has no schooling 
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Sixty-eight patients (93.2%) were on regular folic acid 
supplement, 2 (2.7%) were taking folic acid irregularly, while 
3 (4.1%) were not taking folic acid at all.   
Twelve patients (16.4%) had long-term benzathine 
penicillin, monthly while 61 (83.6%) had never received 
benzathine penicillin.     
None of the patients had received hydroxyl urea for 
treatment. 
3.2.2     Past history: 
It was observed that 51 patients (83.6%) of the study 
group had past history of hospitalization.  Among patients 
who had history of hospitalization, 7 (9.6%) had been 
admitted once during the last year, 14 (19.2%) of them had 
been admitted twice, 8 patients (11%) were admitted three-
times and 32 patients (43.8%) were admitted more than 
three-times within the last year. (Table 7).  
 It was also found that 48 patients (65.8%) of the 
study group had history of blood transfusions. 
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Table (7):  Number of hospital admission of study group 
Number of hospital 
admissions 
 
No 
 
% 
 None 12 16.4 
Once 7 9.6 
Twice 14 19.2 
Three times 8 11.0 
Four times and more 32 43.8 
Total 73 100.6 
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Fifteen patients (20.5%) were transfused once within 
the last year, 13 patients (17.8%) were transfused twice, 7 
(9.7%) patients were transfused three times, and 13 patients 
(17.8%) were transfused more than three-times within the 
last year. (Table 8)   
Presenting symptoms and signs at the time of 
previous admissions were variable.  Pallor was found in 48 
patient (94.1%), 40 (78.4%) had infections, 23 (45.1%) 
patients had jaundice, 46 patients (90.2%).  Acute chest 
syndrome 10 (19.6%) had back or abdominal pain. 
34 (66.7%) had fatigability and 5 patients (9.8%) were 
operated. (Figure 9) 
 
3.3 Clinical Signs: 
 The general condition of all patients was well on 
presentation.  It was observed that, the weight of 42 
patients 63.6% of the patients was below the third centile, 
while the height of 26 patients 39.4% were below the third 
centile. (Figure 10:1, 11) 
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Table (8):  Number of Blood Transfusion for study group 
Number of blood 
transfusion 
No % 
No 25 34.2 
Once 15 20.5 
Twice 13 17.8 
Three times 7 9.6 
More than three 
times 
13 17.8 
Total 73 100 
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♣ Respiratory rate more than 30/minute was 
found in 4 patients 5.5%. 
♣ No creptations or ronchi were detected. 
♣ Hemic murmur were detected in 23 patients 
31.5% 
♣ Palpable second heart sound were found in 8 
patients (11%). 
♣ Splenomegally was found in 8 patients (11.0%) 
in the age group of 5-9 years. 
Hepatomegally was found in the majority of patient 45 
(61.6%) patient. 
 
3.4 Investigations: 
 3.4.1   Haemoglobin concentration: 
 In patients with SCA 39 patients 53.4% had 
haemoglobin below, 25 patients 34.2% at the mean, while 
only 9 patients 12.3 their haemoglobin were above the mean 
for age. (Table 9) 
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Table (9):  Hb Level in study group 
 
Hb Level gm/dl No % 
Above the mean 9 12.3 
At the mean 25 34.3 
Below the mean 39 53.4 
Total 73 100.0 
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3.4.2 Lung function test: 
3.4.2.1 Peak expiratory flow rate: 
PEFR was found above the 80% of the predicted value 
for height in 50 patients (68.5%), while it was less than 80% 
of the predicted value for height in 23 patients (31.5%). 
(Figure 11) 
In those with reduced PFER, 10 (43.5%) were in the 
age from 5-9 years, 8 (34.8%) were in the age from > 10-14 
years, while 5 (21.7%) were in the age from > 14 – 18 years. 
The difference between the age groups was not 
statistically significant. P = 0.742 
3.4.2.2 Forced expiratory volume in one   second 
(FEVI): 
FEVI was found above the 80% of the predicted value 
for height in 41 (56%), while it was below the 80% of the 
predicted value for height in 32 (43.8%). (Figure 12) 
They were13patients40.6% in the age group from 5 – 
9 years,also 13 patients 40.6% were in the age group from > 
10 – 13 years, while 6 patients (18.8%) were in the age group 
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> 14 – 18 years.  The difference between the age groups was 
not statistically significant.               P = (0.103) 
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 3.4.2.3   Forced vital capacity (F.V.C.) 
 F.V.C was found above the 80% of the predicted value 
in 39 patients (53.4%), while it was below the 80% of the 
predicted value [ with normal FEVI] in 34 patients (46.6%). 
(Figure 13) 
 In those with reduced F.V.C. [with normal FEV1], 14 
patient (41.2%) in the age group 5 – 9 years, 12 patients 
(35.3%) in the age group > 9 – 13 years, while 8 patients 
(23.5%) were in the age group > 13 – 18 years. 
 The difference between the age groups was not 
statistically significant. (P = 0.460) 
3.4.2.3   Reduced FEV1 and reduced F.V.C with 
normal  EFVI/FVC 
Those who have both F.V.C. and FEV1 below 80% of 
the predicted value for height, were 5 patients (6.8%). 
In this group one patient 20% in the age group from 5 
– 9 years, three patients (60%) in the age group > 9 – 13 
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years, while one patient 20.0% in the age group > 13 – 18 
years. 
The difference between the age groups was not 
statistically significant (P = 0.257). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 86
 
 
 
 
 Severity index was calculated for all patients, 29 
patients (39.7%) were found to be sever cases, 22 patients 
(30.1%) were moderate cases, while 22 patients (30.1%) 
were mild cases. (Figure 14) 
 Five patients (21.7%) with reduced PEF were found to 
be mild cases, 10 (43.5%) were moderate cases, while severe
  cases were found in 8 (34.8%). 
 The difference between the groups was not 
statistically significant (P = 0.22). 
 Seven patients (21.9%) with reduced FEVI and normal 
F.V.C were mild cases, 12 (37.5%) were moderate cases, 
while 13 (40.6%) of them were sever cases, the difference 
was not statistically significant P = 0.346 
 Six patients (17.6%) of reduced F.V.C (with normal 
FEVI) were mild case, 14 (41.2%) were moderate cases, while 
14 (41.2%) also were sever cases. 
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 The difference between the groups was statistically 
significant (P = 0.05). (Figure 15) 
 All the patients with reduced both FEV1 and F.V.C 
were sever cases. This was found to be statistically 
significant (P = 0.001) 
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 In patients with reduced PEF, 17 (73.9%) had history 
of acute chest syndrome, while only 6 patients (26.1%) had 
no history of acute chest syndrome. 
 The difference between the two group was statistically 
significant (P = 0.004). 
 Among patients with reduced FEVI [and normal F.V.C] 
20 (62.5%) had history of acute chest syndrome, while 12 
(37.5%) had no history of acute chest syndrome. 
 The difference between the two group was statistically 
significant (P = 0.012). 
 Among patients with reduced F.V.C (with normal 
FEVI), 21 (61.8%) had history of acute chest syndrome, 
while 13 patients (38.2%) had no history of acute chest 
syndrome. 
 The difference between the two group was statistically 
significant (P = 0.047). (Figure 16) 
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 All the patients with reduced both FEVI and F.V.C 
had history of acute chest syndrome. 
 This was found to be statistically significant (P = 
0.001). 
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 Among patients with reduced PEF, 8 (34.8%) had Hb 
level above the mean for age and sex, 12 (52.2%) at the 
mean, while 3 (13.0%) their Hb level were below the mean.  
The difference between the groups was not statistically 
significant (P = 0.987). 
    In patients with reduced FEVI and normal F.V.C, 10 
(31.3%) their Hb level was above the mean for age and sex, 
17 (53.1%) patients their Hb level at the mean, while five 
(15.6%) their Hb level was below the mean. The difference 
between the groups was not statistically significant (P = 
0.483). 
    Among patients with reduced F.V.C. (and normal 
FEVI) 10 patients (29.4%) had Hb level above the mean, 18 
patients (52.9%) their Hb at the mean, while in 6 patients 
(17.6%), their Hb level below the mean.  The difference 
between the groups was not statistically significant (P = 
0.387). 
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 Among patients with reduced both FEVI and FVC, two 
40% patients  their Hb level above the mean for age and sex, 
while three (60%) patients their Hb level at the mean. None 
of the patients had Hb level below the mean.   The difference 
between the groups was not statistically significant (P = 
0.685). 
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Chapter Four 
 
4- DISCUSSION 
 
4.1 Age characteristics: 
The majority 56 (77%) of children, whom were 
studied, were in the age group from 5-13 years, while only 
17 (23%) of them were in the age group > 13 – 18 years.  
This may indicate decrease life span with age due to 
different complications of SCA.  This is similar to what was 
reported in other studies(7). 
 
4.2 History: 
4.2.1 Family and social history: 
The majority of the patients in the study group were 
of low socioeconomic status.  This is a true reflection of our 
country social status.  Poverty is predominant feature in the 
Sudanese social context. 
The majority of patients with SCA 42 (63%) were from 
Misseria tribe.  The majority of the patients 42 (63%) were 
born to either first degree or second degree cousin 
marriages.  This is a common phenomenon among 
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Sudanese people.  Many of the sibs of the patients 35 (48%) 
had sickle cell anaemia, this can be explained by these 
consanguineous marriages, since sickle cell anaemia is an 
inherited disease.  Similar results were reported in studies 
done in Kenya and Sudan(10). 
Regarding the education of patients with SCA, 15 
(20.5%) had no schooling and among those who had 
schooling 17 (23.3%) had regular school attendance, while 
21 (29%) had irregular school attendance, 20 (27%) repeat   
a year.  This may be due to their repeated hospital 
admissions and crises. 
The majority of the patients 68 (93%) on regular folic 
acid supplements. 
Regarding vaccination only 2 (3%) of children were 
vaccinated against pneumococcal and hepatitis B-infections, 
none of the patients in the study group was vaccinated 
agains HI infection,  although it was proved in previous 
studies(127-129), that patients with sickle cell anaemia have 
impaired immunologic functions of the spleen, they are 
susceptible to the most serious infectious complication, 
specially pneumococcal sepsis, and they do respond 
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normally to intramuscularly administered antigen, such as 
pneumococcal vaccine(124). 
4.2.2     Past history: 
 It was found that the majority of the patients 51 (84%) 
had past history of hospitalization, and 48 (66%) of the 
patients had history of blood transfusions. 
 The pattern of sickle cell anaemia observed in this 
study group is comparable to the sever type described for 
African(9,12).  It was observed that there is high incidence of 
anaemia 48 (65.7%), infections 40 (54.7%) jaundiced 23 
(31.5%) and acute chest syndrome 46 (63%).  A great deal of 
similarity was observed when the pattern of sickle cell 
anaemia in this group was compared in the African 
pattern(9,12).  Foot and hand syndrome was not reported 
because all the children studied were above five years. 
 
4.3 Clinical Signs: 
 Growth retardation was observed in the majority of 
patients of SCA.  This was similar to what was reported in 
similar studies done in Jamaica and Africa(56-58). 
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 Only 4 (5.5%) of the patients had increased 
respiratory rate, while all the children had normal 
respiratory finding, apart from 5.5% who had increased 
respiratory rate, because all the children in our study group 
were in the steady state, so patients with acute chest 
syndrome, or any crisis were not seen. 
 
4.4 Investigations: 
4.4.1    Hb level: 
 Regarding Hb level in patients with SCA, about half of 
the patients had Hb levels below the mean, and about one 
third were found to have Hb levels at the mean, while 9 
(12%) only their Hb levels were above the mean.  This is 
similar to the finding in other studies done in Africa by 
sergeant G.R and Powars D.R(38,45). 
4.4.2 Lung function test: 
4.4.2.1 Peak Expiratory Flow Rate (PEFR) 
PEFR was reduced in one third of the patients, this is 
similar to what was found by Paul Pianosi and co-
workers(122), and also similar to what Bowen EF and co-
worker(130). 
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There is a positive correlation between the reduction 
of PEFR and past history of A.C.S, similar to what Bowen 
and co worker found(130). 
4.4.2.2 Forced expiratory volume in one second 
FEVI 
          Obstructive Lung Disease was found in 32 (43%), this 
similar to what was found in Tunis(125) and Nigeria(126), and 
slightly higher than what Santoli(86) and Koumbourlis AC(85) 
was found. 
 This may be due to repeated A.C.S in our study 
group, there is a positive correlation between obstructive 
Lung Disease and past history of A.C.S.  
4.4.2.3Forced vital capacity: 
           Reduced F.V.C. i.e. restrictive lung disease was 
found 46% of the study group.  This is less than what 
Tunisian were found (125), but similar to Nigerian study(126), 
and Kuwaiti study(124).  It is more than what Santoli and co-
worker found(86). 
The differences may be due to difference in the 
number of the attacks of previous A.C.S.   
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In our study there is a positive correlation between 
past history of A.C.S and restrictive lung disease, this is 
similar to what was found in the previous studies(118).  This 
may be due to the repeated infarction and infection of the 
lung which may end in lung fibrosis(118), which is evident by 
lung C.T. 
4.4.2.4 Reduced FEV1 and Reduced F.V.C.: 
 Both obstructive and restrictive lung disease was 
found in 5 (6%) of the patients. 
 This is less than what Santoli(86) was found but similar 
to what was found in Nigeria(126). 
 There is a positive correlation between restrictive – 
obstructive pattern and both the past history of A.C.S and 
severity of sickle cell anaemia. 
 This may be the worst affection of the lung in sickle 
cell anaemia. 
? There is no correlation between lung 
function test result and severity of sickle cell 
anaemia, except in the obstructive-
restrictive pattern. 
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? There is no correlation between lung 
function test result and Hb level, this 
expected because anemia mainly affect 
diffusion, and not the lung volumes. 
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CONCLUSIONS 
 
• The majority of the patients were 
from Misseria tribe with low family 
income. 
• Pure obstructive, pure restrictive 
or combined restrictive and 
obstructive lung functions were 
detected in patients with sickle 
cell anaemia. 
• Previous attacks of acute chest 
syndrome appeared to affect the 
lung function. 
• The severity of sickle cell anaemia 
appeared to affect the lung 
function. 
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RECOMMENDATIONS 
 
(1) Increase the awareness of the population 
that SCA is an inherited disease to avoid 
the consanguineous marriage, and to 
screen the couple before marriage for Hbs 
carriage. 
(2) Vaccination with Pneumococcal and 
Haemophilus Influenzae, type B and 
influenza vaccines are highly 
recommended. 
(3) Antibiotic prophylaxis regiment, to 
diminish the risk of recurrent bacterial 
infections in young children. 
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(4) Hydroxyl urea treatment to decrease the 
crisis rate, by increasing the proportion of 
fetal hemoglobin. 
(5) Chronic transfusion program, to decrease 
the percentage of sickle cell haemoglobin 
in order to decrease the number of crisis. 
(6) Periodic assessment of the lung function 
of sickle cell anaemia patient, to detect the 
early development of sickle cell chronic 
lung disease. 
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